Is long-term GLP-1 use safe is the right question to ask before you commit years to a medication, and the honest answer has two halves. The first half is genuinely reassuring: the longest controlled safety data now stretch past three years, and in the largest trial of its kind, semaglutide was associated with fewer cardiovascular events than placebo, not more. The second half is the part a sales page will not give you: nobody has years-five-through-ten data yet, obesity is a chronic condition, and what makes long-term use responsible is not a promise. It is the monitoring behind the prescription. This page walks through what the trials actually measured, which risks are real, and what our clinicians watch every 90 days inside our medical weight loss program.
- The SELECT trial followed 17,604 adults for a mean of 39.8 months and found a 20% reduction in cardiovascular death, nonfatal heart attack or nonfatal stroke with semaglutide.
- Established risks are gastrointestinal and mostly dose-related; gallbladder disease and pancreatitis are reported less commonly.
- The boxed warning is specific: a personal or family history of medullary thyroid carcinoma, or MEN2, is a contraindication.
- Weight regain after stopping is common in the trials, which is why maintenance is a plan to design, not an accident to drift into.
- Our flat $299 fee means nothing in our practice earns more when your dose goes up, so deprescribing stays on the table.
What the trials actually measured
Three trials anchor this conversation, and each answers a different part of the question.
STEP-1 established the efficacy picture: over 68 weeks, adults with overweight or obesity taking semaglutide 2.4 mg lost on average about 15% of body weight, with individual results varying widely around that average. You can read the trial directly in the New England Journal of Medicine.
SURMOUNT-1 did the same for tirzepatide over 72 weeks, with the highest dose reaching up to roughly 22.5% average weight loss in that trial's population. Again, averages from a trial population, not a forecast for any individual. The paper is here.
SELECT is the trial that matters most for the long-term safety question, because it was designed to answer it. More than 17,600 adults with established cardiovascular disease and overweight or obesity, but without diabetes, were followed for a mean of 39.8 months on weekly semaglutide 2.4 mg. The result was a 20% reduction in the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, a benefit that appeared early and held. That is not a promise of the same outcome for everyone; it is evidence that in a large, carefully followed population, years of exposure did not surface a hidden cardiovascular harm. The full paper is here.
The risks that are real, and how they are managed
Honesty first: no medication is without risk, and a clinician who recites only benefits is telling you about their business model, not the drug.
Gastrointestinal effects are the most common by a wide margin: nausea, vomiting, diarrhea and constipation, concentrated around dose increases. They are managed by slower titration, dietary structure and, when needed, holding the dose rather than climbing past tolerability. A program whose default answer to side effects is a higher dose is telling you something.
Gallbladder disease and pancreatitis are reported less commonly and belong on the list because rapid weight loss itself raises some of the same risks. They are part of why the follow-up in a serious program is clinical, not a refill button.
The boxed warning is the one people mean when they say thyroid. The label carries a warning about medullary thyroid carcinoma based on rodent studies, with human relevance not established, and a hard contraindication: a personal or family history of MTC, or Multiple Endocrine Neoplasia syndrome type 2, means these medications should not be used. The FDA's own labeling language is public and unambiguous; see the Ozempic prescribing information. This is precisely why a screening intake exists: a family history of medullary thyroid cancer or MEN2 changes the entire recommendation, and it is the kind of fact that only surfaces when someone actually asks.
Muscle loss is the concern we hear most from readers who have done their homework, and it deserves a straight answer. Weight loss on any effective therapy includes some lean mass. The countermeasure is not a different drug; it is protein intake, resistance training and quarterly body-composition tracking, which is exactly what the membership's Biomarker Audit cycle is built around.
What we watch every 90 days
The trial follow-up above was dense and deliberate. Real-world care should be a lighter-weight version of the same thing, not a refill queue. Our Biomarker Audit runs every 90 days and is included in the membership: ApoB and Lp(a) for the atherogenic particle picture, hs-CRP for inflammation, HbA1c and fasting insulin for the metabolic trend, a full thyroid panel, and hormone markers where the clinical picture calls for them. How those markers drive treatment decisions is described in what the labs show, and the panel's logic is laid out in the advanced labs beyond a standard lipid panel.
The point of the cadence is not decoration. If a medication is on board for years, every renewal is a question: is this dose still earning its place against your markers, your side-effect history and your goals? A dose that only ever goes up is not a treatment plan; it is a subscription with a steering wheel that only turns one way.
One flat fee for the doctor. Zero markup on the medicine.
The forever question, answered honestly
The trials are blunt about what happens when the medication stops: for many participants, weight comes back, partly because the biology the drug works on does not go away. Staying on therapy long term is therefore a legitimate, evidence-supported plan for many people. It is not the only plan, and it should never be the assumed one.
Some patients reach a stable maintenance dose and stay there for years. Some step down after their markers and their goals change. Some stop and transition the work to the clinical relationship, which is precisely what a membership with a clinician can hold that a prescription app cannot. What we will not do is decide for you that higher is the default. Our fee is $299 a month at every dose, and the medication is billed by your pharmacy at the pharmacy's own price with nothing added by us, so nothing in our economics gets better when your dose does. The structural reasoning is in Aligned Medicine and the zero-markup model.
Who should not take a GLP-1 at all
Anyone with a personal or family history of medullary thyroid carcinoma, or with MEN2, should not take these medications; the boxed warning exists for exactly this. A history of pancreatitis, certain gallbladder conditions and pregnancy or active plans for pregnancy each change the conversation too. None of this is a formality: it is the difference between a clinician who screens before prescribing and a checkout button that prescribes after.
What this means if you are already a year or five in
If you have been on a GLP-1 for a long time and your care has been a shipping notification and a scale, the question is not whether to quit; it is whether anyone has re-justified the therapy against your current labs. That re-justification is one Biomarker Audit and one honest visit away. Bring your dose history and whatever old labs you have; we start from the data you already paid for. And if you are comparing programs before committing years, the structural differences are laid out plainly in are telehealth weight loss programs effective and in why we will never prescribe compounded GLP-1s.
FAQ
Is long-term GLP-1 use safe? The longest controlled data run past three years and show cardiovascular benefit rather than new harms in a large population. Years five through ten have no controlled data yet, so responsible long-term use means staying monitored: a comprehensive panel every 90 days and a clinician who re-justifies the dose against it.
What are the established risks? Gastrointestinal effects are most common and mostly dose-related; gallbladder disease and pancreatitis are reported less commonly. Medullary thyroid carcinoma carries a boxed warning, and a personal or family history of MTC or MEN2 is a contraindication.
Do I have to take it forever? Weight regain after stopping is common in the trials, so staying on therapy is a legitimate plan. It is not the only one; maintenance dosing, step-downs and deprescribing are all clinical options that should be revisited against your labs every quarter.
What gets monitored? HbA1c and fasting insulin, a full thyroid panel, ApoB, Lp(a), hs-CRP, and hormone markers where relevant, alongside weight, blood pressure and body composition. Our Biomarker Audit runs this every 90 days, included in the membership.
Does the membership include the medication? No. Two separate charges: the clinician at a flat $299 a month after a $598 start that covers the first two months, and the medication billed by your pharmacy at its own price with nothing added by us.
What if my family has thyroid cancer in its history? A personal or family history of medullary thyroid carcinoma or MEN2 rules these medications out. Other thyroid cancers generally do not, but the history belongs in your chart and your clinician's decision, surfaced at intake before anything is prescribed.
Sources
- SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, New England Journal of Medicine, 2023 (nejm.org)
- STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, 2021 (nejm.org)
- SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity, New England Journal of Medicine, 2022 (nejm.org)
- Ozempic prescribing information, FDA label, boxed warning and contraindications (fda.gov)